Seborrheic Dermatitis Clinical Trial
Official title:
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Seborrheic dermatitis is a common and recurrent dermatosis that characteristically involves the scalp, nasolabial folds, eyebrows, glabella, and upper eye lids. It presents as an erythematous, thin scaly patch with a greasy sandpaper texture that varies depending on disease severity. While seborrheic dermatitis most frequently occurs on the face, it can involve other areas of the body especially the chest, abdomen, and axilla. Overall incidence is thought to be between 2-5% of the general population, though this is likely an underestimation. Pruritus is variable, though the signs and symptoms of this disorder are certainly worsened by certain external conditions especially weather, personal perspiration, stress, and poor hygiene. Patients often complain about the red, scaly patches on the face. Antifungal agents are frequently used as monotherapy or in combination regimens in the treatment of seborrheic dermatitis. Topical corticosteroids are often used for their anti-inflammatory effects. Long term use of topical steroids on the face is not a preferred treatment modality due to the risk of striae development and other textural changes that occur over time. Therefore, topical crisaborole may be an alternative given its non-corticosteroid anti-inflammatory action. Crisaborole is a phosphodiesterase-4 (PDE-4) inhibitor that increases intracellular cyclic AMP (cAMP) levels to exert its anti-inflammatory effects. While it has not previously been investigated for its effects in seborrheic dermatitis, further studies evaluating its role in this disease are warranted. Therefore, the investigators propose a proof of concept study using topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01703793 -
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
|
Phase 2 | |
Completed |
NCT01203189 -
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
|
N/A | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Recruiting |
NCT03688971 -
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
|
Phase 2 | |
Recruiting |
NCT01139749 -
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
|
Phase 4 | |
Completed |
NCT05105139 -
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
|
||
Completed |
NCT01591070 -
Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis
|
Phase 4 | |
Completed |
NCT05787860 -
Ruxolitinib in Seborrheic Dermatitis
|
Phase 2 | |
Completed |
NCT00403559 -
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
|
Phase 2 | |
Not yet recruiting |
NCT00767546 -
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
|
Phase 1 | |
Terminated |
NCT01315951 -
Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation
|
N/A | |
Recruiting |
NCT05942248 -
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
|
N/A | |
Recruiting |
NCT06013371 -
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
|
Phase 2 | |
Recruiting |
NCT05319444 -
Cleansing Device for the Treatment of Scalp and Hair Conditions
|
N/A | |
Completed |
NCT04445987 -
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
|
Phase 2 | |
Completed |
NCT04973228 -
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
|
Phase 3 | |
Completed |
NCT03114111 -
Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis
|
Early Phase 1 | |
Completed |
NCT02656368 -
Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
|
N/A | |
Completed |
NCT00830908 -
HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis
|
N/A | |
Completed |
NCT02349854 -
Neurobiology of the Scalp in Seborrheic Dermatitis
|
N/A |